LDL-C Assessment With PCSK9 Monoclonal Antibody Inhibition Combined With Statin Therapy-2
Status:
Completed
Trial end date:
2013-12-04
Target enrollment:
Participant gender:
Summary
The primary objective was to evaluate the effect of 12 weeks of evolocumab administered
subcutaneously every 2 weeks (Q2W) and monthly (QM) when used in combination with a statin,
compared with placebo, on percent change from baseline in low-density lipoprotein cholesterol
(LDL-C) in patients with primary hypercholesterolemia and mixed dyslipidemia.